Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on May 14, 2026. The report addresses a significant regulatory milestone for the company's lead therapeutic candidate.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the U.S. Food and Drug Administration (FDA) granting Fast Track designation to XPro™ (pegipanermin). This designation applies to the treatment of early Alzheimer's disease (AD). Pegipanermin is described as the company's first-in-class selective soluble TNF inhibitor.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the FDA Fast Track designation. The filing does not provide specific financial guidance, updated clinical trial timelines, or a detailed discussion of risks and contingencies beyond the context of the regulatory approval. No unusual items were reported.
Investor Verification Checklist
- Verify the specific criteria met by XPro™ (pegipanermin) to qualify for FDA Fast Track designation.
- Review the attached press release (Exhibit 99.1) for details on the clinical data supporting the designation.
- Confirm the current clinical development stage of pegipanermin for early Alzheimer's disease.
- Assess the potential impact of Fast Track designation on the company's regulatory timeline and capital requirements.